Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Taysha Gene Therapies Inc.

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Taysha Gene Therapies yesterday and set a price target of $13.00. The company’s...

Cantor Fitzgerald Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)

Piper Sandler analyst Biren Amin maintained a Buy rating on Taysha Gene Therapies today and set a price target of $9.00. According to TipRanks, Ami...

Piper Sandler Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)

Truist Financial analyst Joon Lee maintained a Buy rating on Taysha Gene Therapies today. The company’s shares closed yesterday at $4.27. Lee cover...

Taysha Gene Therapies (TSHA) Receives a Rating Update from a Top Analyst

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Taysha Gene Therapies (TSHA – Research Report) and Day One Biopha...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TSHA	$4.19	+5.01%	4.39M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TSHA	$4.19	+5.0%	4.39M
3
4
5
6

TSHA

TSHA

No Data Available

Get Taysha Gene Therapies Inc. Data in Excel

Get Taysha Gene Therapies Inc. Data in Excel